The Chinese drug administration approved China Resources Double-Crane Pharmaceutical's (SHA:600062) supplementary application to increase the specifications of sugammadex sodium injection, according to a Shanghai Stock Exchange filing on Wednesday.
The specification of the drug will be raised to 5 milliliters:500 milligrams.
The drug is used for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults and for the reversal of rocuronium-induced blockade in children and adolescents, the pharmaceutical company said.
A new drug approval number that will be valid for 12 months will be issued.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。